Related Experiment Video
Updated: Sep 6, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Betting on Biology: Rethinking Probability as the Currency of Risk in Biotechnology Portfolios
1Independent Researcher, Princeton, New Jersey, USA. rk.emax@proton.me.
Abstract:
Uncertainty is an integral facet to the biotechnology and life sciences industry. From early target drug discovery to regulatory approval and commercialization, investment decisions are made under conditions of incomplete knowledge and asymmetric information. Indices of probability, particularly probability of technical and regulatory success, probability of clinical success, and risk-adjusted net present value, have become foundational tools for structuring these uncertainties within portfolio decision-making frameworks. However, their interpretation and application often lack conceptual precision and contextual nuance. This commentary examines the use of probability indices in describing and managing portfolio risk in biotechnology and life sciences. It reflects on their role in assigning risk to new drug targets, novel therapeutic modalities, and stage-specific development programs.
Related Concept Videos
Probability Laws
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Biostatistics: Overview
Discrete variables are...
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Overview of Biostatistics in Health Sciences
Mutation, Gene Flow, and Genetic Drift
